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study question: Is there any difference in the clinical performance of the 3-year one-rod etonogestrel (ENG)- and the 5-year two-rod
levonorgestrel (LNG)-releasing contraceptive implants during 3 years of insertion, and between implant and intrauterine device (IUD) contra-
ception, in particular complaints possibly related to hormonal contraceptives?
summaryanswer: The cumulative contraceptive effectiveness after 3 years andmethod continuation through 2.5 years were not signiﬁ-
cantly different between ENGand LNG implants, but both outcomeswere signiﬁcantly worse in the non-randomized age-matched group of IUD
users than in the combined implant group.
what is known already: ENG- and LNG-releasing implants are safe and highly efﬁcacious contraceptives with pregnancy rates
reported to be 0.0–0.5 per 100 women-years (W-Y). No head-to-head comparative study of the two implants has been undertaken, and
little information is available on comparisons of complaints of side effects of implant and copper IUD users.
study design, size, duration: This was an open parallel group RCTwith 1:1 allocation ratio of the ENG and the LNG implants with
non-randomized control group of women choosing TCu380A IUD to address lack of reliable data on common side effects typically attributed to
the use of progestogen-only contraceptives. After device(s) placement, follow-upswere at 2weeks, 3 and 6months, and semi-annually thereafter
for 3 years or until pregnancy, removal or expulsion of the implant/IUD occurred.
participants, setting, methods: The study took place in family planning clinics in Brazil, Chile, Dominican Republic, Hungary,
Thailand, Turkey and Zimbabwe. Women seeking long-term contraception were enlisted after an eligibility check and informed consent, and
2982womenwereenrolled: 1003, 1005 and 974 in the ENG-implant, LNG-implant and IUDgroups, respectively; 995, 997and 971, respectively,
were included in the per protocol analysis reported here.
main results and the role of chance: ENG and LNG implants each had the same 3-year cumulative pregnancy rate of 0.4 per
100W-Y [95% conﬁdence interval (CI) 0.1–1.4]. A weight of ≥70 kg at admission was unrelated to pregnancy. Method continuation rates for
ENGandLNG implants at 2.5 yearswere69.8 (95%CI66.8–72.6) and71.8per 100W-Y (68.8–74.5), and at3 years 12.1 (95%CI5.2–22.0) and
† The list of WHO study group participants is given in the Appendix.
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52.0 per 100W-Y (95% CI 41.8–61.2), respectively. Bleeding disturbances, the most frequent reason for method discontinuation, were signiﬁ-
cantly more common in the ENG group [16.7 (95% CI 14.4–19.3)] than in the LNG group [12.5 (95% CI 10.5–14.9)] (P 0.019). The 3-year cu-
mulative loss to follow-up was lower in the ENG- than in the LNG-implant group, 8.1 (95% CI 6.4–10.2) and 14.4 per 100 W-Y (95% CI
12.1–17.1), respectively. The median duration of implant removal was 50 s shorter among women with ENG than among women with LNG
implant (P, 0.0001). In the observational comparison between IUD and implant users, the 3-year relative risk for pregnancy in IUD group com-
paredwith the combined implant groupwas 5.7 per 100W-Y (95%CI 4.4–7.3) (P ¼ 0.0003). The 3-year expulsion rate of the IUDwas 17.8 per
100W-Y (95% CI 14.5–21.9), while the discontinuation rate for bleeding disturbances was 8.5 (95% CI 6.7–10.9). Frequency of complaints of
headache and dizziness was not signiﬁcantly different between implant and IUDusers (P ¼ 0.16 and 0.77, respectively), acne and bleeding irregu-
larities weremore frequent among implant users (P, 0.0001), while heavy bleeding and lower abdominal pain occurredmore often among IUD
than implant users (P, 0.0001).
limitations, reasons for caution: Few women were ≤19 years old or nulligravida, the proportion of implant users ≥70 kg
was ,20% and ,8% were obese.
wider implications of the findings: Findings of the study can inform policy makers and clinicians about choice of implant, but
also about TCu380A IUD in relation to implants.
study funding/competing interest(s): UNDP/UNFPA/WHO/UNICEF/WorldBank Special ProgrammeofResearch,De-
velopment and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR),World Health Or-
ganization (WHO). This report contains the views of an international expert group and does not necessarily represent the decisions or the stated
policy of the WHO.
trial registration: ISRCTN33378571 registered on 22 March 2004. The ﬁrst participant was enrolled on 12 May 2003.
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Introduction
Contraceptive implants together with the levonorgestrel (LNG)- and
copper-bearing intrauterine devices (IUDs) are long-acting reversible
contraceptives (LARC) that give high contraceptive effectiveness without
requiring attention, coitus related or otherwise, by the users (Grimes,
2009). A recent study (Winner et al., 2012) showed that these methods
weremore effective in preventing unintendedpregnancies than contracep-
tive pills, patch and rings, with cumulative pregnancy rates up to 3 years
of 0.9 per 100 women-years (W-Y); in comparison, contraceptive pills,
patch and ring had pregnancy rates .20 times that of the LARC methods.
The high effectiveness of LARC was equal at different women’s ages,
whereas younger women using pills, patch or ring had signiﬁcant more
frequent contraceptive failures than older women (Winner et al., 2012).
The contraceptive implants available include the one-rod 3-year
etonogestrel (ENG) implant (Implanonw), the two-rod 5-year LNG
(Jadellew) implant and another 4-year two-rod LNG-releasing implant
manufactured in China (Sino-implant II). For the implants, annual preg-
nancy rates are reported being between 0.0 and 0.5 per 100 W-Y
(Glasier, 2002; Bahamondes et al., 2014).
The two-rodLNG- and theENG-releasing implants ﬁrst receiveddrug
regulatory approvals in 1996 and 1998, respectively; however, no com-
parative trial evaluating the two implants has been done (Meirik et al.,
2003). Consequently, the UNDP/UNFPA/WHO/UNICEF/World
BankSpecial ProgrammeofResearch,Development andResearchTrain-
ing inHumanReproduction (HRP/WHO) initiated amulticentreRCTof
the two implants with a non-randomized control group of users of the
TCu380A IUD. The latter group was added to obtain comparative
data on incidence of non-serious side effects typically attributed to the
use of progestogen-only contraceptives (Brache et al., 2002). Results
regarding the methodology of the trial and data on insertion of implants
and IUDs, and 6 weeks post-insertion follow-up have been published
(Meirik et al., 2013). This article reports results for 3-year follow-up
and focusses on contraceptive efﬁcacy, reasons for method discontinu-
ation and continuation rates, side effects of the three methods and
data from implant removals.
Materials andMethods
This was an open label parallel RCT with 1:1 allocation ratio of the
ENG-releasing implant (Implanonw, Merck & Co., Inc., Whitehouse
Station, NJ, USA) and the LNG-releasing implant (Jadellew, Bayer Health-
care, Berlin, Germany), and a non-randomized age-matched group of
women choosing TCu380A IUD (Pregnaw, Pregna International, Mumbai,
India). The study was approved by the Scientiﬁc and Ethical Review Group
at HRP/WHO, WHO Secretariat Committee on Research Involving
Human Subjects and by the Ethics Committee of all participating centres.
The methods of the study have been reported elsewhere (Meirik et al.,
2013). Brieﬂy, the study took place in family planning clinics in Campinas,
Brazil; Santiago, Chile; Santo Domingo, Dominican Republic; Szeged,
Hungary; Bangkok, Thailand; Ankara (three sub-centres), Turkey; and
Harare, Zimbabwe. Women seeking LARC methods were informed about
the study including the randomization of implants; that the implants and
IUDs and the insertions and removals would be without cost for the
women; and that if randomized to ENG implant, there would be a free
choice of a replacement implant at no cost after removal of the original
ENG implant at 3 years. Eligible women willing to participate signed an
informed consent form before entering the study. Follow-up was for 3
years or until accidental pregnancy, removal or expulsion of the implant/
IUD, whatever occurred ﬁrst. About midway through the study, it was
decided to extend the follow-up including the use of the ENG implant to 5
years. Results of the extended follow-up will be reported separately.
Randomization
The randomization sequence for implant users was computer generated at
HRP/WHO with variable block size of six or eight and stratiﬁed by centre.
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For potential implant users, the centres received a list of centre-speciﬁc
unique subject numbers and a set of opaque sealed envelopes also with
subject numbers. At admission, women received a subject number, and im-
mediately before implant insertion, the envelope with the subject number
was opened and a slip informed about implant allocation. Women in the
IUD group were matched by age (in 5-year bands) to every second woman
allocated to an implant.
Participating women
The inclusion criteriawere as follows: non-pregnant clinically healthywomen
aged ≥18 and ,45 years, with regular menstrual cycles, ≥6 weeks post-
partum, able to keep a menstrual diary and willing to return to the clinic for
follow-up visits. Exclusion criteria for implant and IUD acceptors were those
published byWHO in Medical Eligibility Criteria for Contraceptive Use, 2nd
Ed. (WHO, 2000). Implant and IUD insertions were performed within the
ﬁrst 5 days of menstrual cycle by trained healthcare professionals (HCPs):
physicians, nurses or midwives. Follow-up visits were scheduled 2 weeks
and 3 months after insertion and every 6 months thereafter.
Outcomes
The study focusses on contraceptive efﬁcacy, discontinuation of use and safety
of the methods. Diagnosis of pregnancy was based on clinical signs and symp-
toms,urinepregnancy testsandultrasoundexaminations.Reasons for removal
of the implant/IUD were medical (expulsion, bleeding problems and other
medical reasons) and personal (wish for pregnancy, moving out of reach and
other personal reasons). At each follow-up visit, women were speciﬁcally
asked if they had any complaints of headache, dizziness, acne, their own
perception of vaginal bleeding patterns and lower abdominal pain, followed
by questions about their health condition in general. Pelvic inﬂammatory
disease (PID) was deﬁned as having complaints of lower abdominal pain;
receiving a diagnosis according to ICD 10 codes N70, N71, N73, N74.3 or
N74.4; and systemic treatment with antibiotics; whenever judged necessary,
information about potential PID and other conditions was obtained from
other health facilities the woman had consulted. Duration of implant
removal was the time (minutes, seconds) it took from when the scalpel
touched the skin until a compress was placed on the site of the removal.
Sample size
A sample of 2000women randomized to the ENGor LNG implants (1000 in
each arm), with 1000 women in the TCu380A IUD group, was aimed at
based on the following assumptions: 40% of implant or IUD users would
discontinue the use of themethod, losses to follow-up would be 5% and dis-
continuations and losses would be evenly distributed over the 3 years.With
80%of power and 5% signiﬁcance level in two-sided tests, the chosen sample
would allow detection of a 1.6 per 100 W-Y difference in the cumulative
3-year pregnancy rate, assuming a cumulative rate of 0.5 per 100 W-Y; a
7% difference in the 3-year cumulative discontinuation rate, assuming that
the rate of stopping implant use altogetherwould be 40%; and a 6–8%differ-
ence in the 3-year cumulative rate of perceived side effects, assuming that the
rate would be between 25 and 35%.
Data management and statistical analysis
Data were managed in HRP/WHO, Geneva, Switzerland through August
2006 and from September 2010 and onwards. From September 2006
through August 2010, the Centro Rosarino de Estudios Perinatales (CREP),
Rosario, Argentina, managed the data. Participating centres sent originals
of completed case report forms to HRP/WHO and CREP at regular inter-
vals. Regular on-site monitoring of the participating centres according to
GoodClinical PracticeGuidelines started in 2006 andwasdone by personnel
from Family Health International, Research Triangle Park, NC, USA and
HRP/WHO project manager. The data were analysed in HRP/WHO in
per protocol manner using SAS/STAT version 9.2 (SAS, 2011). The survival
plots were generated using R software, Version 2.14.2 (R Development
Core Team, 2012).
Only women without any protocol violations as detected by the time of
analysis were included in the data analysis. Comparisons between the
groups were made using the Pearson x2 test (two sided) for categorical
outcome variables. Risk ratios (RRs) with 95% conﬁdence interval (CI)
were computed for binary repeated outcomes using the generalized estimat-
ing equation (GEE) log-binomial model. Kaplan–Meier (K–M) method was
used to estimate the overall method continuation rates, and the cumulative
risk of discontinuation, by reason. Time from insertion was computed in
months. For the present report, we used the K–M estimates for women
who discontinued the method up to 38 months after insertion. All women
who came in the window 34–38 months and who did not remove the
implant/device were censored at this visit.
The log-rank test, stratiﬁed for centre,was used toassess differences at the
end of ﬁrst, second and third years. Depending on the outcome variable, the
data are presented asmean+ standard deviation (SD), survival rates, cumu-
lative hazard rate (HR) and relative risk (RR) with 95% CI. Signiﬁcance was
established at P, 0.05. To do a comparison of continuation rates of the
groups that was independent of the scheduled 3-year removal of ENG
implants, sensitivity analyses estimated the continuation rates at 2.5 years
(30months) of use and at 34months. In another sensitivity analyses, the ana-
lytical approach of intention to treat (ITT) was applied, where all participants
were analysed according to the group of device allocation.
Results
Enrolments occurred from 12 May 2004 to 31 January 2008. A total of
2008 women accepted to be randomized to use of ENG or LNG
implant, and 974 women chose TCu380A IUD and agreed participation
in the study (Fig. 1). Altogether, 995, 997 and 971women starting use of
the ENG implant, LNG implant and IUD, respectively, are included in the
current per protocol analysis.
Details about the number of women enrolled in each centre as well as
the main demographic and reproductive characteristics in the three
groups were published previously (Meirik et al., 2013). In brief, the
mean (+SD) age of the participants was 27.7+6.2, 28.1+ 6.4 and
28.7+6.6 years, for the ENG-implant, LNG-implant and IUD groups,
respectively. Women ≤35 years old represented 84.5% of the entire
sample. Mean (+SD) weight at admission was 60.5+10.9, 60.8+
10.8 and 64.6+12.9 kg, for the ENG-implant, LNG-implant and IUD
groups, respectively. Less than 20% of both groups of implant users
weighed .70 kg, whereas 30.3% of women choosing the IUD weighed
.70 kg at admission.More than80%of thewomenweremarriedorcoha-
biting, and only less than 5% were nulligravidas. Among thosewith at least
one pregnancy, .95% reported that the last pregnancy ended in a live
birth. More than 95% reported ever previous contraceptive use, and
near 70% had used hormonal contraceptives. Almost 15% of the implant
users had previously used implants, while one-third of IUD users had
used copper IUDs before. The main characteristics of the three groups
were similar with the only exception being that the number of nulligravidas
was slightly lower in the IUD group.
ENG versus LNG implant
The 3-year cumulative pregnancy rate was 0.4 per 100 W-Y (95% CI
0.1–1.4) for each group of ENG- and LNG-implant users (Table I and
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Fig. 2). Among 196 LNG users weighing ≥70 kg at admission, one preg-
nancy occurred (0.8 per 100W-Y) (95%CI 1–5.3) and none among 184
ENG users. At the time of the conception of the three pregnancies in
LNG-implant users, all three women weighed ≥70 kg, whereas the
three conceptions among the ENG-implant users occurred at weight
,70 kg. One of the three pregnancies in LNG-implant users was
ectopic and none among ENG-implant users.
Bleeding disturbances were the most frequent reason for discontinu-
ation of use in both groups of implant users, reaching 3-year cumulative
rates of 16.7 per 100 W-Y (95% CI 14.4–19.3) and 12.5 per 100 W-Y
(95% CI 10.5–14.9) for ENG and LNG implants, respectively (Table I)
(P ¼ 0.019). One expulsion occurred about 6 months after insertion
in the LNG-implant group. At 1 and 2 years, there were no differences
in continuation rates for the two implants (Table I and Fig. 3). In the sen-
sitivity 1 and 2 analysis at 2.5 years (30 months), rates were also similar,
69.8 per 100W-Y (95% CI 66.8–72.6) and 71.8 per 100W-Y (95% CI
68.8–74.5) for ENG and LNG implants, respectively, and at 34 months
(Fig. 3). As expected, the method continuation rate by the end of 3
years (38 months) was higher in the LNG-implant group [52.0 per 100
W-Y (95% CI 41.8–61.2)] compared with ENG group [12.1 per 100
W-Y (95% CI 5.2–22.0)]. For the calculation of the continuation rates
in this 3-year study (seeMaterials andMethods section),womenattending
the 3 years (34–38 months) follow-up visit and consenting to be further
followed up were censored by the date of their clinic visit. Six hundred
and sixteen women in the ENG-implant group, 595 in the LNG-implant
group and 450 in the IUD group attended the 3-year (34–38 months)
follow-up visit; of thesewomen, 235ENG-implant users, 57 LNG-implant
usersand41 IUDusersdiscontinueduseof their implant/IUD.Among the
235 of ENG-implant users having the implant removed during the 3-year
visit, 101 (42%) accepted the offer to have a new implant inserted. After
Figure 1 Flowchart of women screened for eligibility and admitted for use of implant or IUD, women randomized to type of contraceptive implant and
reasons for non-inclusion in analysis. 1Fourwomen changed theirmind about implant use after randomization and before implant insertion. 2Bymistake, the
type of implants was swapped. ENG, etonogestrel; LNG, levonorgestrel; IUD, intrauterine device.
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Table I Cumulative numbers and rates per 100with 95% conﬁdence limits (CL) of reason for stopping implant use in ﬁrst through third years after initiation of use,
and overall method discontinuation and losses to follow-up by the type of implant.
Variable First year Second year Third year1
ENG implant LNG implant ENG implant LNG implant ENG implant LNG implant
No. of women starting interval 995 997 857 843 717 721
Pregnancy, all 1; 0.1 (0.0–0.8) 0; 0.0 1; 0.1 (0.0–0.8) 0; 0.0 3; 0.4 (0.1–1.4) 3; 0.4 (0.1–1.4)
Medical reason for stopping implant use
Medical reason, all 68; 7.1 (5.6–8.9) 64; 6.7 (5.3–8.5) 140; 15.2 (13.0–17.6) 110; 12.0 (10.0–14.3) 172; 19.1 (16.7–21.8) 138; 15.5 (13.3–18.1)
Bleeding problems, all 57; 6.0 (4.6–7.7) 48; 5.1 (3.9–6.7) 122; 13.4 (11.3–15.8) 87; 9.7 (7.9–11.8) 148; 16.7 (14.4–19.3) 109; 12.5 (10.5–14.9)
Other medical 11; 1.2 (0.6–2.1) 15; 1.6 (1.0–2.6) 18; 2.0 (1.3–3.2) 22; 2.4 (1.6–3.7) 24; 2.9 (1.9–4.3) 28; 3.3 (2.3–4.8)
Personal reasons for stopping implant use
Personal reasons, all 44; 4.6 (3.5–6.2) 54; 5.8 (4.4–7.5) 98; 10.9 (9.1–13.2) 110; 12.2 (10.3–14.6) 137; 16.0 (13.7–18.6) 142; 16.4 (14.0–19.0)
Planning pregnancy 8; 0.9 (0.4–1.7) 11; 1.2 (0.7–2.2) 29; 3.5 (2.4–5.0) 29; 3.5 (2.4–5.0) 52; 6.7 (5.2–8.8) 42; 5.4 (4.0–7.2)
Other personal reason 35; 3.7 (2.7–5.1) 43; 4.6 (3.4–6.1) 67; 7.5 (5.9–9.4) 76; 8.5 (6.8–10.5) 82; 9.5 (7.7–11.7) 94; 10.9 (9.0–13.2)
Moved out of reach 1; 0.1 (0.0,0.7) 0; 0.0 2; 0.2 (0.1,1.0) 5; 0.6 (0.3,1.4) 3; 0.4 (0.1,1.2) 6; 0.7 (0.3,0.7)
Continuation rates and losses to follow-up
Overall continuation rate 88.5 (86.3–90.3) 87.9 (85.7–89.8) 75.4 (72.6–78.0) 77.2 (74.4–79.7) 12.1 (5.2–22.0) 52.0 (41.8, 61.2)
Lost to follow-up 24; 2.5 (1.7–3.8) 35; 3.6 (2.6–5.0) 38; 4.3 (3.1–5.8) 53; 5.8 (4.5–7.6) 65; 8.1 (6.4–10.2) 115; 14.4 (12.1–17.1)
Released from follow-up 0; 0.0 0; 0.0 0; 0.0 0; 0.0 0; 0.0 0; 0.0
ENG, etonogestrel; LNG, levonorgestrel.
1Third year corresponds to the time period of 25th through 38th months, see text.
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having been informed about off-label continued use of the ENG implant,
381 women consented either in writing (365 women) or verbally
(16 women) to continue the use of it and be followed up further.
Losses to follow-up were similar albeit somewhat lower in the ENG-
than in the LNG-implant group; by the end of 3 years, it was 8.1 per 100
W-Y (95%CI 6.4–10.2) and 14.4 per 100W-Y (95%CI 12.1–17.1), re-
spectively (Table I).
The frequency of symptoms and signs reported in the course of the
study by ENG- or LNG-implant users is shown in Table II together
with diagnoses of PID. Apart from more reports from ENG-implant
users about amenorrhoea, therewere no signiﬁcant differences recorded
between the two implant groups. The median time for removal of the
implant was shorter in the ENG group than in the LNG-implant group
(P, 0.0001) (Table III) andwasreportedaseasybyHCPs inagreaterpro-
portion among ENG users when compared with the LNG group (P,
0.0001). In seven LNG- and in two ENG-implant removals, breakage of
one of the rods occurred during removal (P, 0.031), although removal
was complete. One woman needed a sedation to remove the implant
Figure 2 Survival curves with pregnancy occurrence from device insertion up to 3 years of follow-up.
Figure 3 Continuation rates from device insertion up to 3 years of follow-up.
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due to difﬁculty in removal. Women’s perception of moderate to severe
pain at implant removal was low and similar (,3%) among the two
groups of users.
Implants versus IUD
The 3-year cumulative pregnancy rate for the TCu380A IUDusers of 2.8
per 100 W-Y (95% CI 1.3–6.0) was signiﬁcantly higher than the com-
bined rate of 0.4 per 100 W-Y (95% CI 0.2–1.0) for users of ENG and
LNG implants [relative risk 5.7 (95% CI 4.4–7.3)] (P ¼ 0.0003)
(Table IV). Ectopic pregnancies occurred in 2 of the 14 pregnancies in
the IUD group. While the risk of a diagnosis of PID was similar
between ENG- and LNG-implant users, among women using IUD the
3-year cumulative incidence of an episode of at least one diagnosis of
PID was 0.69 per 100 W-Y compared with 0.22 per 100 W-Y in
implant users (P, 0.0001).Among the IUDusers, the3-year cumulative
discontinuation rate for bleeding disturbances was signiﬁcantly lower
than among implant users, 8.5 per 100 W-Y (95% CI 6.7–10.9) and
14.6 per 100W-Y (95% CI 13.1–16.4), respectively (P, 0.0001). Cu-
mulative expulsion rates of the copper IUD for the ﬁrst, second and third
years of use were 9.4 per 100 W-Y (95% CI 7.7–11.6), 13.1 per 100
W-Y (95% CI 11.0–15.6) and 17.8 per 100 W-Y (95% CI 14.5–21.9),
respectively. Other medical reasons for removal of the IUD or implant
were more frequent in the IUD users than in the implant users
(Table IV). The 3-year continuation rate in the IUD group was 49.7
per 100W-Y (95% CI 45.3–54.0) and higher than that of the combined
implant group.However, by 2.5 years, the continuation rate for the com-
bined implant group was signiﬁcantly higher than that of the IUD group,
70.8 per 100W-Y (95% CI 68.7–72.8) and 62.3 per 100W-Y (95% CI
59.1–65.4), respectively (P, 0.0001). The results of the ITT sensitivity
........................................................ ........................................................
.............................................................................................................................................................................................
Table II Numbers and GEE estimates of occurrence of symptoms, signs and conditions during use of ENG and LNG
implants, and ratio of estimate with 95% CL.
Symptoms, signs,
conditions
ENG implant LNG implant RR2 (95% CI) P-value
No. with ≥1
complaint1
Risk estimate, per
1002
No. with ≥1
complaint1
Risk estimate per
1002
Headache 593 31.3 574 31.9 1.0 (0.89–1.08) 0.72
Dizziness 443 17.9 432 18.9 0.9 (0.83–1.07) 0.37
Acne 450 17.3 423 18.7 0.9 (0.81–1.05) 0.22
Lower abdominal pain 501 20.2 452 22.1 0.9 (0.81–1.03) 0.14
Amenorrhoea 387 18.7 464 15.2 1.2 (1.08–1.41) 0.001
Irregular bleeding 856 48.7 858 48.3 1.0 (0.95–1.07) 0.76
Heavy bleeding 352 13.0 393 11.6 1.1 (0.97–1.29) 0.11
Prolonged bleeding 559 22.6 568 22.0 1.0 (0.93–1.14) 0.58
PID 12 0.2 12 0.2 1.1 (0.47–2.48) 0.85
1The number of women in whom the symptom, sign or condition was reported on at least at one of the follow-up visits.
2Binomial GEE model with log and identity links, model with study group only.
ENG: etonogestrel; LNG: levonorgestrel.
........................................................ ........................................................
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Table III Numbers and GEE estimates of occurrence of symptoms, signs and conditions during use of contraceptive
implants (ENG and LNG) and TCu380A IUD, and ratios of GEE estimate with 95% CIs of implant versus IUD.
Symptoms, signs,
conditions
ENG and LNG implants TCu380A IUD RR2 (95% CI) P-value
No. with ≥1
complaint1
Riskestimate, per
1002
No. with ≥1
complaint1
Riskestimate, per
1002
Headache 1167 31.6 517 33.6 0.9 (0.88–1.02) 0.16
Dizziness 875 18.4 388 18.7 1.0 (0.88–1.10) 0.77
Acne 873 18.0 313 13.1 1.4 (1.20–1.56) ,0.000
Lower abdominal pain 953 21.2 594 35.8 0.6 (0.54–0.65) ,0.000
Amenorrhoea 851 16.9 84 2.7 6.3 (5.00–8.33) ,0.000
Irregular bleeding 1714 48.5 378 13.66 3.6 (3.23–4.00) ,0.000
Heavy bleeding 745 12.3 484 23.9 0.5 (0.47–0.58) ,0.000
Prolonged bleeding 1127 22.3 417 19.0 1.2 (1.05–1.30) 0.002
PID 24 0.2 26 0.7 0.3 (0.18–0.58) 0.000
1The number of women in whom the symptom, sign or condition was reported on at least at one of the follow-up visits.
2Binomial GEE model with log and identity links, model with study group only.
ENG: etonogestrel; LNG: levonorgestrel.
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Table IV Cumulative numbers and rates per 100with 95%CLof reason for stopping implant or IUDuse in ﬁrst through third years after initiationof use, andoverall
method discontinuation and losses to follow-up by implant and IUD.
Variable First year Second year Third year1
Implants TCu380A IUD Implants TCu380A IUD Implants TCu380A IUD
No. of women starting interval 1992 971 1700 698 1438 571
Pregnancy 1; 0.1 (0.0–0.4) 9; 1.1 (0.6–2.2) 1 ;0.1 (0.0–0.4) 10; 1.3 (0.7–2.4) 6; 0.4 (0.2–1.0) 14; 2.8 (1.3–6.0)
Medical reasons for stopping implant use
Medical reasons, all 132; 6.9 (5.8–8.1) 140; 15.2 (13.0–17.7) 250; 13.6 (12.1–15.2) 191; 21.6 (19.0–24.5) 310; 17.3 (15.6–19.2) 228; 28.8 (25.2–32.8)
Device expulsion 1; 0.1 (0.0–0.8) 85; 9.4 (7.7–11.6) 1; 0.1 (0.0–0.8) 112; 13.1 (11.0–15.6) 1; 0.1 (0.0–0.8) 128; 17.8 (14.5–21.9)
Bleeding problems, all 105; 5.5 (4.6–6.7) 33; 3.8 (2.7–5.3) 209; 11.5 (10.2–13.1) 49; 6.1 (4.7–8.1) 257; 14.6 (13.1–16.4) 62; 8.5 (6.7–10.9)
Other medical 26; 1.4 (0.9–2.0) 22; 2.6 (1.7–3.9) 40; 2.2 (1.6–3.0) 30; 3.8 (2.6–5.4) 52; 3.1 (2.4–4.0) 38; 5.2 (3.8–7.1)
Personal reasons for stopping method use
Personal reasons, all 98; 5.2 (4.3–6.3) 57; 6.9 (5.3–8.8) 208; 11.6 (10.2–13.2) 100; 13.0 (10.8–15.6) 279; 16.2 (14.5–18.0) 129; 17.7 (15.1–20.8)
Planning pregnancy 19; 1.0 (0.7–1.6) 20; 2.5 (1.6–3.9) 58; 3.5 (2.7–4.5) 41; 5.7 (4.2–7.7) 94; 6.1 (5.0–7.4) 53; 7.8 (6.0–10.2)
Other Personal 78; 4.1 (3.3–5.1) 36; 4.3 (3.1–5.9) 143; 8.0 (6.8–9.4) 57; 7.5 (5.8–9.6) 176; 10.2 (8.9–11.8) 74; 10.5 (8.4–13.0)
Moved out of reach 1; 0.1 (0.0–0.4) 1; 0.1 (0.0–0.8) 7; 0.4 (0.2–0.9) 2; 0.3 (0.1–0.8) 9; 0.6 (0.3–1.1) 2; 0.3 (0.1–0.8)
Continuation and losses to follow-up
Continuation rate 88.2 (86.7–89.5) 78.0 (75.3–80.6) 76.3 (74.3–78.1) 67.2 (64.1–70.2) 30.3 (23.1–37.9) 49.7 (45.3–54.0)
Lost to follow-up 59; 3.1 (2.4, 4.0) 61; 7.0 (5.5–8.9) 91; 5.1 (4.1, 6.2) 88; 10.9 (8.9–13.3) 180; 11.3 (9.8, 13.0) 142; 19.9 (17.1–23.1)
Released from follow-up 0; 0.0 1; 0.1 (0.0–1.0) 0; 0.0 2; 0.3 (0.1–1.2) 0; 0.0 3; 0.5 (0.1–1.2)
1Third year corresponds to the time period of 25th through 38th months, see text.
IUD: intrauterine device.
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analysis gave results that were almost identical to that of the per protocol
analysis, albeit that in the ITT analysis, the pregnancy rates in the
ENG- and LNG-implant groups were 0.5 W-Y (95% CI 0.2–1.4) and
0.6 W-Y (95% CI 0.3–1.5), respectively.
Among complaints and symptoms reported by women in response
to a question about health problems in general, lower abdominal pain
and ‘heavy bleeding’ were more frequently reported among IUD users
than among implant users (Table V), while implant users more often
reported acne, amenorrhoea, irregular bleeding andprolongedbleeding.
Headache and dizziness were the most frequently reported complaints,
notbeing signiﬁcantly differentbetween the IUDand implant groups.The
risk of PID among implant users was about a third of that of IUD users,
and the RR was 0.3 per 100 W-Y (95% CI 0.2–0.6). The method con-
tinuation rate by group is shown in Fig. 3.
Regarding severe adverse events, there were 12 women who died: 7
from complications due toHIV infection, 1 each due to lung, cervical and
breast cancers, 1 due to viral meningitis and 1 from road accident.
Detailed information on reported serious adverse events is available in
Supplementary data, Annex I.
Discussion
Main ﬁndings in this 3-year study of contraceptive implants and copper
IUDs are that the one-rod ENG and two-rod LNG implants both had
very high and undistinguishable contraceptive efﬁcacy. The continuation
rates for the two implants were similar up to 2.5 years (30 months).
Also, up to 2.5 years, the continuation rate for the two implants combined
was higher than that of theTCu380A IUD. Bleeding disturbanceswere the
most frequent reason for stopping the use of both implants and the
TCu380A IUD, which is in line with previous reports on contraceptive
implants and IUDs (Zheng et al., 1999; Power et al., 2007; O’Brien et al.,
2008). ENG-implant users quoted bleeding disturbances as reason for re-
moving the implant signiﬁcantly more often compared with LNG-implant
users; however, this difference did not lead to any difference of the
overall 2.5-year continuation rate of the two implants. The result of the
ITT sensitivity analysis showed marginally higher pregnancy rates for the
two implants than what was the results of the per protocol analysis. The
reason for the difference is that women who were found to be pregnant
at implant insertion were included as method failures in the ITT analysis.
As expected, the removal of the one-rod ENG implant took less time
and was perceived as easier by medical staff than the removal of the
two-rod LNG implant, although neither the differences of duration of
removal nor ease of it appears being of much clinical signiﬁcance. The
reported perception of pain and lack thereof at implant removal was vir-
tually identical, and about 80% of the women in both implant groups
reported no pain at removal.
Thepattern of complaints and symptomsas reported by implant users
compared with IUD users was in many aspects anticipated; IUD users
.............................................................................................................................................................................................
Table V Difﬁculties and complications at implant removal and pain as perceived by women at, by type of implant.
Observations at removal ENG implant2
No. of removals 546
LNG implant3
No. of removals 340
P-value
Duration of removals (seconds)
Median 68 120 ,0.00001
Interquartile range 39–120 69–195
Range 4–903 4–1200
Mean (SD) 94 (98) 161 (156)
Missing values 27 29
Reported ease of removal
Easy, n (%) 492 (94%) 254 (81%) ,0.0001
Slightly difﬁcult, n (%) 22 (4%) 47 (15%)
Difﬁcult, n (%) 8 (2%) 12 (4%)
Missing values 24 27
Complication at removal1
No 520 (99.6%) 306 (97.8%) 0.031
Yes 2 (0.4%) 7 (2.2%)
Missing values
Women’s perception of pain at removal
None 444 (86%) 252 (81%) 0.068
Mild 65 (13%) 49 (16%)
Moderate 8 (2%) 6 (2%)
Severe 0 3 (1%)
Missing values 29 30
ENG, etonogestrel; LNG, levonorgestrel.
1Of 334 ENG-implant and 292 LNG-implant removals by end of third year, 24 and 24, respectively, had missing values.
2Complications at ENG-implant removals: implant broken (2).
3Complications at LNG-implant removals: implant broken (7) and sedation (1).
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reported more often lower abdominal pain and heavy menstrual bleed-
ing than implant users, while for acne, amenorrhoea, irregular or pro-
longed bleeding, it was the opposite. These observations correspond
with what previously has been found in observational studies of side
effects of users of contraceptive implants and IUDs (Davies et al.,
1993; Kiriwat et al., 1998; Sivin et al., 1998, 2010; Funk et al., 2005).
Headache and dizziness, however, complaints frequently reported to
be associatedwith hormonal contraception, were not signiﬁcantly differ-
ent between the IUD and implant users. PID is a rare condition that can
be difﬁcult to diagnose clinically (Meirik, 2007), and it was less often diag-
nosed in users of implant than in IUD users [relative risk estimate 0.2
(95% CI 0.18–0.58)]. This very low relative risk estimate may reﬂect
reality, but it may also be biased downwards because a priori belief
among some healthcare providers that the IUD is strongly associated
withPIDmaywell have led themtomoreeasily assumeaclinical diagnosis
of PID in users of IUD than in implant users. Current evidence is that the
modern copper IUDs are only weakly associated with PID (Farley et al.,
1992; Hubacher et al., 2013).
Strength of this study is the randomization of the two implants being
studied, albeit the different characteristics of the two implants precluded
a blinded trial. To our knowledge, it is the ﬁrst head-to-head RCT of the
one-rod ENG and the two-rod LNG implants. The ENG implant was
previously compared with the six-capsule LNG implant (Norplantw)
(Zheng et al., 1999) in a smaller RCT 2-year trial that also conﬁrmed
the safety and high contraceptive effectiveness of the implants. Other
strengths of the study were that it was multicentre with centres across
regions of the world with diverse ethnicities and cultural backgrounds
and that it included a comparison group of IUD users. Although
the IUD group was not randomized, it was centre- and age-matched,
allowing comparison of two principally different, hormonal and non-
hormonal, long-term contraceptive methods.
One limitation was that the implant versus IUD comparison was of
observational nature and not a RCT comparison that was done
between the two types of contraceptive implants. The high expulsion
rate observed in the IUD group of users is noteworthy. Information
that reached two of the authors indicates that some batches of the
TCu380A IUDs provided to the study may have had a too narrow
space between the insertion tube and the rod, and, when removing
the rod after having placed the IUD, the threads of the IUD could be
caught between the rod and the tube and dislocate the IUD to a low
position in the uterine cavity (L. Bahamondes andO.Meirik, personal in-
formation, 2006). This problem has since long been corrected. Other
limitations are that of women admitted, few were below the age of
20 years, nulligravidas, overweight or obese. As reported previously
(Meirik et al., 2013), the time period from initiating the study to reporting
it was inﬂuenced by problems associated with delays of some potential
centres in deciding not to participate in the study and with outsourcing
of data management. The former eventually led to an increase in the en-
rolment quota and prolonged the period of enrolment in some partici-
pating centres, and the latter to time-consuming cleaning of data.
A comparison of continuation rates between the ENG and the
LNG implants through 3 years will inevitably be affected by the shorter
approved effective lifespan of 3 years of the ENG implant against 5
years for the LNG implant. In this study, the continuation rate of the
ENG implant was compounded by the offer to continue the use of the
originally inserted ENG implant through the fourth and ﬁfth years after
placement, which many women consented to do after having been
informed about this off-label extension of use of it. Hence, an unbiased
3-year continuation rate for the ENG implant could not be calculated
from data of this study. The K–M estimate was 12.1 per 100 after cen-
soring women who attended the visit that originally was scheduled for
implant removal. However, the continuation rates of the two implants
were very similar up through 2.5 years and also up to 34months, indicat-
ing that the overall balance women make of the contraceptive efﬁcacy,
convenience of use and side effects was similar for the two implants up
to the end of the approved effective lifespan of the ENG implant.
A simpliﬁed calculation of proportion of women having ENG implant
inserted and de facto continued implant contraception beyond 3 years
indicates the following: at start of the34thmonth after implants insertion,
616women in the ENG-implant group, for whom information was avail-
able, were still using the implant. In the period of 34–38 months after
insertion, 235 of the 616 women had their implant removed, and of
these, 101 chose to have a new implant inserted. Another 381 ENG-
implant users being censored during the 34–38 post-insertion interval
chose to continue in the extension of the study and to use the originally
inserted implant beyond 3 years. Thus, 3 years after, 995 women had
ENG implant inserted and 482 (48.4%) women continued or chose to
continue implant contraception. However, the approved shorter life-
span of the ENG implant compared with that of the LNG implant used
in this study does negatively affect continuation rates of implant contra-
ception beyond 3 years.
In conclusion, this RCT showed that the ENG and LNG implants have
the same contraceptive effectiveness and similar reasons for implant
removal for all combined medical reasons in the 3 years after insertion,
continuation rates for the two implants were similar up to the middle
of the third year of use and had, during this time period, higher continu-
ation rates than the TCu380A IUD. The difference of the median of
the duration of removal between the two implants is without clinical
signiﬁcance in the common practice. Comparison of occurrence of
side effects reported by implant and IUD users conﬁrmed that some
complaints usually attributed to progestogen-only contraceptives were
more common among implant users (acne, amenorrhoea, irregular
bleeding) than in IUD users. However, complaints of headache and diz-
ziness frequently attributed to hormonal contraceptiveswere not signiﬁ-
cantly different. Lower abdominal pain and heavy bleeding were more
frequent among IUD users than implant users. The results of the study
can help policy makers to decide which type of implant to introduce in
the family planning programmes.
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